Search 

The University of Deusto (UDEUSTO) is a 125 year old, non-profit university. Beyond research which is co-ordinated from chairs such as Law and the Human Genome, Leisure and Disabilities, there is, in the institutional sphere, a clear option for the social topics of interdependency, distribution of resources, migration, human rights, development, poverty andenvironment, ethics and society. There are also studies about cultural identity (individual and collective), and European integration processes taking part invarious international research groups. Internationalisation, without excluding other regions, demonstrates a clear commitment to Europe and Latin America, having signed agreements with more than 200 universities.
The present proposal would be developed by the International Research Project Office and housed under the Deusto Social Innovation, which is the knit for knowledge transfer and outreach at the University of Deusto in the fiel of Social Research and Innovation. Our goal is to provide solutions to local and international changes and challenges of society, to contribute to the improvement and transformation towards a just and balanced development.
The experience of UDEUSTO in international projects is evidenced by its track records including 91 international networks and over 60 EU funded projects, including 4 Framework Programmes Initial Training Networks Marie Curie actions.

 

Founded more than 70 years since its origin Zeltia group has been involved in the biopharmaceutical and chemical. Zeltia publicly traded since 1963 and in the continuous market since 1998.

The holding is a world-leading biopharmaceutical company specialised in the development of marinebased drugs for use in oncology and central nervous system illnesses. Grupo Zeltia consists mainly of the following companies: PharmaMar, the world-leading biotechnology company in advancing cancer
care through the discovery and development of innovative marine-derived medicines; Noscira, a biotech firm focused on discovering and developing new drugs against Alzheimer’s disease and other neurodegenerative diseases of the central nervous system; Genomica, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and a chemical division comprising Zelnova and Xylazel, two highly profitable companies that are leaders in their respective market segments.